Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors and/or degradation inducers reported to be useful for the treatment of psoriasis, cancer, rheumatoid arthritis, asthma and more.